Please assess the completion status of the following clinical trial:

Trial Title: AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma~  * Recurrent or persistent disease~* Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded) as ≥ 20 mm by conventional techniques or as ≥ 10 mm by spiral CT scan~  * Must have at least one target lesion that can be used to assess response, as defined by RECIST criteria~    * Tumors within a previously irradiated field will be designated as non-target lesions unless progression is documented OR a biopsy is obtained to confirm persistent disease ≥ 90 days following completion of radiotherapy~* Must have received one prior platinum-based chemotherapeutic regimen containing carboplatin, cisplatin, or another organoplatinum compound for management of primary disease~  * Initial treatment may have included high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment~ * One additional cytotoxic regimen for management of recurrent or persistent disease allowed~ * Patients must have a platinum-free interval of \< 12 months, have progressed during platinum-based therapy, or have persistent disease after a platinum-based therapy~* Ineligible for a higher priority GOG protocol~* No pleural effusion or ascites causing grade 2 or greater dyspnea~* No history of uncontrolled CNS metastases~  * Patients with a history of CNS metastases must have their disease controlled by radiotherapy and/or surgery; have at least two imaging scans following treatment (that were no less than 30 days apart) showing no progression of any lesions and no new lesions; and be clinically stable off corticosteroids for ≥ 14 days prior to study randomization~PATIENT CHARACTERISTICS:~* GOG performance status (PS) 0-2\* NOTE: \*Patients who have received 2 prior regimen must have a GOG PS of 0-2 and patients who have received 2 prior regimens must have a GOG PS of 0-1~* ANC ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* Urine protein \< 30 mg/dL by urinalyses or ≤ 1+ by urine dipstick (unless quantitative protein is \< 500 mg by 24-hour urine collection)~* Bilirubin ≤ 1.5 times ULN (\< 3 times ULN in patients with UGT1A1 promoter polymorphism \[i.e., Gilbert syndrome\] confirmed by genotyping or Invader® UGT1A1 Molecular Assay)~* AST and ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)~* Alkaline phosphatase ≤ 2 times ULN (5 times ULN if liver or bone metastases are present)~* PTT normal~* INR ≤ 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Able to swallow oral medications~* Cardiac ejection fraction normal~* No sensory and motor neuropathy \> grade 2~* No other invasive malignancies within the past 5 years, except nonmelanoma skin cancer or other specific malignancies~* No bleeding diathesis or hypercoagulopathy within the past 14 days~* No arterial or venous thrombosis within the past 12 months~* None of the following within the past 12 months:~  * Myocardial infarction~ * Cerebrovascular accident~ * Transient ischemic attack~ * Grade 2 or greater peripheral vascular disease~ * Percutaneous transluminal coronary angioplasty/stent~ * Congestive heart failure~ * Ongoing arrhythmias requiring medication~ * Unstable angina~* No average systolic blood pressure ≥ 150 mm Hg and average diastolic blood pressure ≥ 90 mm Hg~  * Patients with hypertension that is stable on a current dose of anti-hypertensives are eligible~* No history of impaired cardiac status (e.g., severe heart disease, cardiomyopathy, or congestive heart failure)~* No psychiatric, addictive, or other kind of disorder that would compromise the ability of the patient to give written informed consent~* No open wounds, ulcers, or fractures~* No active infection requiring antibiotics (with the exception of uncomplicated UTI)~* No known HIV, hepatitis B, or hepatitis C positivity~* No known hypersensitivity to AMG 706~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered form prior surgery, radiotherapy, or chemotherapy~* At least 1 week since prior hormonal therapy for the malignant tumor~  * Concurrent hormone replacement therapy allowed~* At least 3 weeks since other prior therapy directed at the malignant tumor, including biologic or immunologic agents (i.e., small molecules or murine monoclonal antibodies)~* At least 12 weeks since prior chimeric, human, or humanized monoclonal antibodies~* More than 30 days since prior investigational therapy~* More than 12 weeks since prior bevacizumab~* More than 30 days since prior VEGFR-targeted therapy, including, but not limited to, any of the following:~  * SU5416~ * SU6668~ * Sunitinib malate~ * Vandetanib~ * Vatalanib~ * AZD2171~ * AEE 788~ * Sorafenib~* More than 28 days since prior major surgery~* More than 14 days since prior minor surgery, including open breast biopsy~* More than 7 days since prior core needle biopsy or placement of a central venous access device (including portion, tunneled, or non-tunneled catheters)~* No prior cancer treatment that would contraindicate study therapy~* No prior therapy AMG 706~* No prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer~  * Prior adjuvant chemotherapy for localized breast cancer allowed provided it was completed \> 3 years ago, and the patient remains free of recurrent or metastatic disease~* No prior non-cytotoxic chemotherapy for management of recurrent or persistent disease~* No prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of ovarian, fallopian tube, or primary peritoneal cancer~  * Prior radiotherapy for localized cancer of the breast, head and neck, or skin allowed provided it was completed \> 3 years ago, and the patient remains free of recurrent or metastatic disease~* No concurrent coumadin-type anticoagulants, including warfarin, at doses \> 1 mg/day~  * Concurrent low molecular weight heparin or low dose warfarin (i.e., ≤ 1 mg daily) for prophylaxis against central venous catheter thrombosis is allowed~* No other concurrent investigational or antineoplastic agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- AMG 706 (Type: EXPERIMENTAL): AMG 706 daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues